ARUP LABORATORIES | aruplab.com

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 32 years   Female

Specimen Collected: 07-Sep-22 13:52

Sertraline, Serum or Plasma	Received: 07-Sep-22 13:53		Report/Verified: 07-Sep-22 13:59
Procedure	Result	Units	Reference Interval
Sertraline_Serum or Plasma	201 **H i1**	ng/mL	[30-200]

Test Information

i1:   Sertraline_Serum or Plasma
        REFERENCE INTERVAL: Sertraline, Serum or Plasma

        Therapeutic Range: 30 – 200 ng/mL
        Toxic: Greater than 300 ng/mL

    Sertraline is a selective serotonin reuptake inhibitor antidepressant drug indicated
     for the treatment of major depressive disorder, obsessive-compulsive disorder,
    post-traumatic stress disorder, social anxiety disorder and premenstrual dysphoric
    disorder. Sertraline doses range from 50-200 mg/day to produce serum concentration
    that range from 30-200 ng/mL. Dosing above 200 mg/day may increase the risk of
    adverse effects. Adverse effects may include dry mouth, headache, dizziness,
    fatigue, somnolence, tremor, nausea, and diarrhea. The risk of serotonin syndrome is
     increased with concomitant use of other serotonergic drugs. Concomitant use of
    sertraline with anticoagulants and nonsteroidal anti-inflammatory drugs may increase
     the risk of bleeding.

    This test was developed and its performance characteristics determined by ARUP
    Laboratories. It has not been cleared or approved by the US Food and Drug
    Administration. This test was performed in a CLIA certified laboratory and is
    intended for clinical purposes.

---

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 22-250-900187

Report Request ID: 16417231

Printed: 07-Sep-22 14:01

Page 1 of 1